Vaidya, J; Earl, HM; et al, .; (2019) 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet 10.1016/S0140-6736(19)30650-6. (In press).